Equitable Trust Co. Sells 396 Shares of DexCom, Inc. (NASDAQ:DXCM)

Equitable Trust Co. reduced its holdings in DexCom, Inc. (NASDAQ:DXCM) by 2.1% during the third quarter, Holdings Channel.com reports. The institutional investor owned 18,243 shares of the medical device company’s stock after selling 396 shares during the quarter. Equitable Trust Co.’s holdings in DexCom were worth $1,223,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in DXCM. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of DexCom in the 2nd quarter worth approximately $25,000. Sachetta LLC boosted its position in shares of DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 171 shares in the last quarter. Crewe Advisors LLC bought a new stake in DexCom in the first quarter worth $29,000. Riverview Trust Co boosted its holdings in DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after acquiring an additional 232 shares in the last quarter. Finally, DT Investment Partners LLC boosted its holdings in DexCom by 492.2% in the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after acquiring an additional 315 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have commented on DXCM. Wells Fargo & Company boosted their target price on DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, October 25th. Sanford C. Bernstein boosted their target price on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $145.00 price objective on shares of DexCom in a research report on Tuesday, July 23rd. Stifel Nicolaus increased their price objective on DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, August 23rd. Finally, UBS Group dropped their price objective on DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $104.59.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other DexCom news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by company insiders.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $69.96 on Friday. The firm has a 50 day moving average of $69.66 and a 200 day moving average of $93.70. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The firm has a market capitalization of $27.33 billion, a price-to-earnings ratio of 41.89, a price-to-earnings-growth ratio of 2.10 and a beta of 1.17. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.